AZN
Stock Details
AZN is AstraZeneca PLC's stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 64.83$. Average daily volumn in 3 months 6.94M. Market cap 200.04B
Stock symbol : AZN. Exchange : NasdaqGS. Currency : USD Lastest price : 64.55$. Total volume : 1.04M. Market state REGULAR Click reload if you want to check the lastest price on market!!!
AstraZeneca PLC (AZN)
Last Price
64.55$Change
-1.52Volume
1.04M
| Previous Close | 66.07 |
| Open | 64.10 |
| Day Range | 64.07-64.57 |
| Bid | 64.01 x 1.2k |
| Ask | 63.99 x 1.1k |
| Volume | 1.04M |
| Average Volume | 6.94M |
| Market Cap | 200.04B |
| Beta | 0.12 |
| 52 Week Range | 53.63-71.70 |
| Trailing P/E | N/A |
| Foward P/E | 16.90 |
| Dividend (Yield %) | 2.18% |
| Ex-Dividend Date | 2022-02-24 |
Financial Details
Organization
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolis... m diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Market Cap:
200.04BRevenue:
37.42BTotal Assets:
105.36BTotal Cash:
6.33B
News about "AstraZeneca PLC"
Oxford Biomedica, AstraZeneca Extend COVID-19 Vaccine Manufacturing Partnership
Source from : Nasdaq - 14 hours ago
Oxford Biomedica plc (OXB.L) said that it has signed a new three year master services & development agreement with AstraZeneca UK Ltd which would facilitate potential future manufacturing ...See details»
Spire Wealth Management Trims Position in AstraZeneca PLC (NASDAQ:AZN)
Source from : Defense World - 11 hours ago
Spire Wealth Management cut its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Get Rating) by 18.0% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 10,219 ...See details»
S.Korea authorises AstraZeneca COVID therapy Evusheld for vulnerable people
Source from : Reuters - 1 days ago
South Korea on Thursday authorised AstraZeneca PLC's antibody-based therapy for preventing COVID-19 infection in people with a poor immune response, increasing its options as it works to ease the ...See details»
AstraZeneca signs new three-year deal with Oxford Biomedica for COVID shot
Source from : Seeking Alpha - 10 hours ago
U.K.-based biotech Oxford Biomedica (OXBDF) announced on Friday that the company entered into a new three-year partnership with AstraZeneca (AZN) to manufacture the Anglo ...See details»
AstraZeneca: Imfinzi Plus Chemotherapy Improved PCR In Resectable Lung Cancer - Quick Facts
Source from : Nasdaq - 1 days ago
Thursday announced positive high-level results from a planned interim analysis of the AEGEAN Phase III trial that evaluated Imfinzi (durvalumab) plus chemotherapy in resectable non-small cell lung ...See details»
Oxford BioMedica Extends Agreement With AstraZeneca for Covid-19 Vaccine Facility
Source from : MarketWatch - 14 hours ago
By Michael Susin Oxford BioMedica PLC said Friday that it has signed an extended agreement with AstraZeneca UK Ltd. for the use of its facility to ...See details»
SMALL-CAP WINNERS & LOSERS: Oxford BioMedica rises on AstraZeneca deal
Source from : London South East - 11 hours ago
Oxford BioMedica PLC, up 4.6% at 475.01 pence, 12-month range 414.00p-1,678.00p. The gene and cell therapy company signs a new three-year agreement with AstraZeneca PLC, which will facilitate ...See details»
Oxford BioMedica signs new Covid-19 vaccine deal with AstraZeneca
Source from : Buy - 13 hours ago
Oxford BioMedica PLC on Friday said it has signed a new three year agreement with AstraZeneca PLC, which will facilitate potential future manufacturing opportunities for the FTSE 100-listed ...See details»
Wealthcare Advisory Partners LLC Lowers Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)
Source from : Defense World - 2 days ago
Wealthcare Advisory Partners LLC lowered its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Get Rating) by 6.0% during the first quarter, according to its most recent disclosure with the ...See details»
What You Need To Know About AstraZeneca PLC's (LON:AZN) Investor Composition
Source from : Yahoo Style Australia - 2 days ago
The big shareholder groups in AstraZeneca PLC ( LON:AZN ) have power over the company. Insiders often own a large ...See details»
CAPROCK Group Inc. Has $640,000 Position in AstraZeneca PLC (NASDAQ:AZN)
Source from : ETF Daily News - 7 days ago
CAPROCK Group Inc. increased its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Get Rating) by 45.5% during the first quarter, HoldingsChannel reports. The institutional investor owned 9,643 shares ...See details»
Short Volatility Alert: AstraZeneca PLC
Source from : Benzinga.com on MSN.com - 9 days ago
On Tuesday, shares of AstraZeneca PLC (NASDAQ: AZN) experienced volatile short activity. After the activity, the stock price went up 2.85% to $62.83. The overall ...See details»
AstraZeneca-Daiichi Sankyo Enhertu breast cancer drug recommended for EU approval
Source from : MarketWatch on MSN.com - 4 days ago
The decision was based on trial results showing that Enhertu cut the risk of disease progression or death by 72% compared with the trastuzumab emtansine drug.See details»
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
Source from : Benzinga.com - 4 days ago
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Enhertu (trastuzumab deruxtecan) and Lynparza (olaparib) for breast cancer ...See details»